Thompson E Aubrey
Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, USA.
Mol Cells. 2007 Oct 31;24(2):167-76.
Peroxisome proliferator-activated receptor-gamma (PPARgamma) is expressed at very high levels in the gastrointestinal epithelium. Many of the functions of PPARgamma in gastrointestinal epithelial cells have been elucidated in recent years, and a pattern is emerging which suggests that this receptor plays an important role in gastrointestinal physiology. There is also strong evidence that PPARgamma is a colon cancer suppressor in pre-clinical rodent models of sporadic colon cancer, and there is considerable interest in exploitation of PPARgamma agonists as prophylactic or chemopreventive agents in colon cancer. Studies in mice and in human colon cancer cell lines suggest several mechanisms that might account for the tumor suppressive effects of PPARgamma agonists, although it is not in all cases clear whether these effects are altogether mediated by PPARgamma. Conversely, several reports suggest that PPARgamma agonists may promote colon cancer under certain circumstances. This possibility warrants considerable attention since several million individuals with type II diabetes are currently taking PPARgamma agonists. This review will focus on recent data related to four critical questions: what is the physiological function of PPARgamma in gastrointestinal epithelial cells; how does PPARgamma suppress colon carcinogenesis; is PPARgamma a tumor promoter; and what is the future of PPARgamma in colon cancer prevention?
过氧化物酶体增殖物激活受体γ(PPARγ)在胃肠道上皮中高水平表达。近年来,PPARγ在胃肠道上皮细胞中的许多功能已被阐明,一种模式正在显现,表明该受体在胃肠道生理学中发挥重要作用。也有强有力的证据表明,在散发性结肠癌的临床前啮齿动物模型中,PPARγ是一种结肠癌抑制因子,并且人们对开发PPARγ激动剂作为结肠癌的预防或化学预防剂有相当大的兴趣。对小鼠和人类结肠癌细胞系的研究表明了几种可能解释PPARγ激动剂肿瘤抑制作用的机制,尽管并非在所有情况下都清楚这些作用是否完全由PPARγ介导。相反,一些报告表明PPARγ激动剂在某些情况下可能促进结肠癌。鉴于目前有数百万II型糖尿病患者正在服用PPARγ激动剂,这种可能性值得高度关注。本综述将聚焦于与四个关键问题相关的最新数据:PPARγ在胃肠道上皮细胞中的生理功能是什么;PPARγ如何抑制结肠癌发生;PPARγ是肿瘤促进剂吗;以及PPARγ在结肠癌预防中的未来如何?